Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Shingrix in Allogeneic Stem Cell Transplant Recipients
NCT05775718Phase 2Recruiting
- Sponsor
- University of Colorado Denver
- Start
- Oct 2023
- Primary completion
- Jan 2028
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Zoster vaccine recombinant in herpes zoster (HZ), sponsored by University of Colorado Denver. Started Oct 2023; status: recruiting.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT05775718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05775718.